| Name | Title | Contact Details |
|---|
OncoNano Medicine is developing a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease.
At BioNTech we believe that every cancer patient’s treatment should be individualized. Our vision is to provide patient-specific immunotherapies worldwide.
Kymanox is a professional services organization with a focus on project delivery. Our team of experts provide guide you and your project.
ImmunityBio is a vertically-integrated, clinical-stage biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The company`s range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. We are applying our science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases.
BIOAGE has a diverse team of computational biologists and medical scientists with expertise in aging and translational research. We share the vision that a synergy of machine learning approaches, high throughput human omics data, and new experimental approaches will make it possible to discover therapies that address unmet medical needs in an aging population.